ECSP10010735A - Compuestos químicos 251 - Google Patents
Compuestos químicos 251Info
- Publication number
- ECSP10010735A ECSP10010735A EC2010010735A ECSP10010735A ECSP10010735A EC SP10010735 A ECSP10010735 A EC SP10010735A EC 2010010735 A EC2010010735 A EC 2010010735A EC SP10010735 A ECSP10010735 A EC SP10010735A EC SP10010735 A ECSP10010735 A EC SP10010735A
- Authority
- EC
- Ecuador
- Prior art keywords
- pim
- relates
- chemical compounds
- kinase
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
La invención se refiere a compuestos químicos de fórmula I; y sales de los mismos. En algunas realizaciones, la invención se refiere a inhibidores o moduladores de la actividad o función enzimática de la proteína quinasa PIM-1 y/o PIM-2 y/o PIM-3. En otras realizaciones adicionales, la invención se refiere a composiciones farmacéuticas que comprenden compuestos descritos en la presente y su uso en la prevención y tratamiento de afecciones y enfermedades relacionadas con la quinasa PIM, preferiblemente cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7763908P | 2008-07-02 | 2008-07-02 | |
US18327809P | 2009-06-02 | 2009-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP10010735A true ECSP10010735A (es) | 2011-01-31 |
Family
ID=41050276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2010010735A ECSP10010735A (es) | 2008-07-02 | 2010-12-30 | Compuestos químicos 251 |
Country Status (27)
Country | Link |
---|---|
US (2) | US8901307B2 (es) |
EP (1) | EP2310010A2 (es) |
JP (2) | JP5261575B2 (es) |
KR (1) | KR20110031367A (es) |
CN (2) | CN102137666B (es) |
AR (1) | AR072791A1 (es) |
AU (1) | AU2009265362B2 (es) |
BR (1) | BRPI0914599A2 (es) |
CA (1) | CA2729557A1 (es) |
CL (1) | CL2010001636A1 (es) |
CO (1) | CO6341555A2 (es) |
CR (1) | CR20110016A (es) |
DO (1) | DOP2010000408A (es) |
EA (1) | EA018989B1 (es) |
EC (1) | ECSP10010735A (es) |
HN (1) | HN2010002786A (es) |
IL (1) | IL210127A0 (es) |
MX (1) | MX2010014233A (es) |
MY (1) | MY155961A (es) |
NI (1) | NI201100007A (es) |
NZ (1) | NZ590859A (es) |
PE (1) | PE20120304A1 (es) |
SV (1) | SV2011003786A (es) |
TW (1) | TWI461423B (es) |
UY (1) | UY31952A (es) |
WO (1) | WO2010001169A2 (es) |
ZA (1) | ZA201100844B (es) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI468162B (zh) | 2005-12-13 | 2015-01-11 | 英塞特公司 | 作為傑納斯激酶(JANUS KINASE)抑制劑之經雜芳基取代之吡咯并〔2,3-b〕吡啶及吡咯并〔2,3-b〕嘧啶 |
SG10201509887UA (en) | 2007-06-13 | 2016-01-28 | Incyte Corp | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
TWI461423B (zh) * | 2008-07-02 | 2014-11-21 | Astrazeneca Ab | 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物 |
EA025520B1 (ru) | 2009-05-22 | 2017-01-30 | Инсайт Холдингс Корпорейшн | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ |
SG176111A1 (en) | 2009-05-22 | 2011-12-29 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
WO2011028685A1 (en) | 2009-09-01 | 2011-03-10 | Incyte Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
MX347851B (es) | 2010-03-10 | 2017-05-16 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). |
EP2574168B9 (en) | 2010-05-21 | 2016-10-05 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
WO2012068450A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
CA2839767A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
WO2013051672A1 (ja) * | 2011-10-04 | 2013-04-11 | 株式会社ヤクルト本社 | チアゾリジン誘導体又はその塩を有効成分とする医薬品 |
CN104203923B (zh) | 2012-03-30 | 2016-08-10 | 乐敦制药株式会社 | 新的苯亚甲基吡咯烷衍生物或其盐 |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
US9630976B2 (en) | 2012-07-03 | 2017-04-25 | Ono Pharmaceutical Co., Ltd. | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes |
BR112015010663B1 (pt) | 2012-11-15 | 2022-12-06 | Incyte Holdings Corporation | Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo |
WO2014110574A1 (en) | 2013-01-14 | 2014-07-17 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
SG10201705662WA (en) | 2013-01-15 | 2017-08-30 | Incyte Corp | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
CN105189509B (zh) | 2013-03-06 | 2017-12-19 | 因赛特公司 | 用于制备jak抑制剂的方法及中间体 |
JP6378918B2 (ja) * | 2013-04-03 | 2018-08-22 | 株式会社ヤクルト本社 | チアゾリジン誘導体又はその塩を有効成分とするPim阻害剤 |
US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
RS60469B1 (sr) | 2013-08-07 | 2020-07-31 | Incyte Corp | Dozni oblici sa produženim oslobađanjem za jak1 inhibitor |
PE20160532A1 (es) | 2013-08-23 | 2016-05-21 | Incyte Corp | Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim |
WO2015046390A1 (ja) * | 2013-09-27 | 2015-04-02 | ロート製薬株式会社 | 新規ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物 |
WO2015046389A1 (ja) * | 2013-09-27 | 2015-04-02 | ロート製薬株式会社 | 新規ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物 |
US20170145005A1 (en) * | 2014-02-13 | 2017-05-25 | The University Of Tokyo | Kinase inhibitor |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
JP5857104B2 (ja) * | 2014-06-17 | 2016-02-10 | ロート製薬株式会社 | ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物 |
WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
US9518022B2 (en) | 2014-12-15 | 2016-12-13 | Prosetta Antiviral Inc. | Anti-HIV compounds |
CN105985298B (zh) * | 2015-02-10 | 2018-02-23 | 湖南大学 | 2‑[(5‑卤噻唑‑2‑基)亚氨基]‑5‑亚苄基噻唑啉酮及其制备方法与应用 |
KR102626155B1 (ko) | 2015-03-06 | 2024-01-17 | 비욘드스프링 파마수티컬스, 인코포레이티드. | Ras 돌연변이와 관련된 암의 치료 방법 |
CN106032365B (zh) * | 2015-03-11 | 2018-03-23 | 湖南大学 | 2‑(噻唑‑2‑基)亚氨基‑5‑亚苄基噻唑啉酮及其制备方法与应用 |
WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
KR20180027563A (ko) | 2015-07-13 | 2018-03-14 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린 조성물 |
TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Pim激酶抑制劑之鹽 |
TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
US10912748B2 (en) | 2016-02-08 | 2021-02-09 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
JP7116422B2 (ja) | 2016-04-05 | 2022-08-10 | イミューン センサー リミテッド ライアビリティ カンパニー | cGASアンタゴニスト化合物 |
SG11201810872UA (en) | 2016-06-06 | 2019-01-30 | Beyondspring Pharmaceuticals Inc | Composition and method for reducing neutropenia |
MA45244A (fr) | 2016-06-13 | 2019-04-17 | Cancer Research Tech Ltd | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 |
EP3565812B1 (en) | 2017-01-06 | 2023-12-27 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
JP2020514412A (ja) | 2017-02-01 | 2020-05-21 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | 好中球減少症の低減方法 |
US11319320B2 (en) | 2017-11-06 | 2022-05-03 | Snap Bio, Inc. | PIM kinase inhibitor compositions, methods, and uses thereof |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
WO2019147615A1 (en) | 2018-01-24 | 2019-08-01 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
WO2019152374A1 (en) | 2018-01-30 | 2019-08-08 | Incyte Corporation | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
MX2022012285A (es) | 2018-03-30 | 2023-08-15 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
JP2021527629A (ja) * | 2018-04-26 | 2021-10-14 | メディシナル バイオコンバージェンス リサーチ センター | mTOR阻害剤としての新規化合物及びその用途 |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2023039170A1 (en) * | 2021-09-09 | 2023-03-16 | Musc Foundation For Research Development | Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy |
CN116354901B (zh) * | 2023-04-12 | 2024-04-26 | 郑州大学 | 一种噻唑烷二酮类化合物及其制备方法和应用 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE940525L (en) * | 1988-05-25 | 1989-11-25 | Warner Lambert Co | Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents |
IL113313A (en) * | 1994-04-11 | 1999-09-22 | Sankyo Co | Heterocyclic compounds and pharmaceutical compositions containing the same |
JP3668291B2 (ja) * | 1995-06-16 | 2005-07-06 | 久光製薬株式会社 | 新規なピペリジン誘導体 |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
IL125686A (en) | 1996-02-13 | 2002-11-10 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability |
DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab | 4-anilinochinazolin derivate |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
UA56185C2 (uk) | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
TW577875B (en) * | 1997-01-31 | 2004-03-01 | Shionogi & Co | Pyrrolidine derivatives with inhibitory activity for phospholipase A2 |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
AU6340600A (en) * | 1999-07-01 | 2001-01-22 | Geron Corporation | Telomerase inhibitors and methods of their use |
AU778720B2 (en) * | 1999-08-23 | 2004-12-16 | Kyorin Pharmaceutical Co. Ltd. | Substituted benzylthiazolidine-2,4-dione derivatives |
TW593293B (en) * | 1999-08-23 | 2004-06-21 | Kyorin Seiyaku Kk | Substituted benzylthiazolidine-2,4-dione derivatives |
WO2001034133A2 (en) * | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
CN1431999A (zh) | 2000-05-31 | 2003-07-23 | 阿斯特拉曾尼卡有限公司 | 具有血管损伤活性的吲哚衍生物 |
CN1255391C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管破坏剂的colchinol衍生物 |
MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
US6452014B1 (en) * | 2000-12-22 | 2002-09-17 | Geron Corporation | Telomerase inhibitors and methods of their use |
AU2003255528B2 (en) | 2002-07-10 | 2009-07-16 | Merck Serono Sa | Azolidinone-vinyl fused-benzene derivatives |
KR20060036896A (ko) * | 2003-04-18 | 2006-05-02 | 인사이트 산 디에고 인코포레이티드 | 대사 장애, 암 및 다른 질병의 치료를 위한 치환된이소크로만 화합물 |
US7531556B2 (en) * | 2004-04-28 | 2009-05-12 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
US7714005B2 (en) * | 2004-12-22 | 2010-05-11 | The Ohio State University Research Foundation | Small molecule Bcl-xL/Bcl-2 binding inhibitors |
WO2009064486A2 (en) * | 2007-11-15 | 2009-05-22 | Musc Foundation For Research Development | Inhibitors of pim protein kinases, compositions, and methods for treating cancer |
TWI461423B (zh) * | 2008-07-02 | 2014-11-21 | Astrazeneca Ab | 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物 |
-
2009
- 2009-07-01 TW TW098122261A patent/TWI461423B/zh not_active IP Right Cessation
- 2009-07-01 UY UY0001031952A patent/UY31952A/es not_active Application Discontinuation
- 2009-07-02 CA CA2729557A patent/CA2729557A1/en not_active Abandoned
- 2009-07-02 EA EA201100119A patent/EA018989B1/ru not_active IP Right Cessation
- 2009-07-02 BR BRPI0914599A patent/BRPI0914599A2/pt not_active IP Right Cessation
- 2009-07-02 AU AU2009265362A patent/AU2009265362B2/en not_active Ceased
- 2009-07-02 WO PCT/GB2009/050773 patent/WO2010001169A2/en active Application Filing
- 2009-07-02 AR ARP090102486A patent/AR072791A1/es unknown
- 2009-07-02 JP JP2011515631A patent/JP5261575B2/ja not_active Expired - Fee Related
- 2009-07-02 US US13/000,138 patent/US8901307B2/en not_active Expired - Fee Related
- 2009-07-02 MX MX2010014233A patent/MX2010014233A/es active IP Right Grant
- 2009-07-02 CN CN200980134849.5A patent/CN102137666B/zh not_active Expired - Fee Related
- 2009-07-02 CN CN201410037508.9A patent/CN103804371A/zh active Pending
- 2009-07-02 KR KR1020117002754A patent/KR20110031367A/ko not_active Application Discontinuation
- 2009-07-02 NZ NZ590859A patent/NZ590859A/xx not_active IP Right Cessation
- 2009-07-02 PE PE2010001221A patent/PE20120304A1/es not_active Application Discontinuation
- 2009-07-02 MY MYPI2010006322A patent/MY155961A/en unknown
- 2009-07-02 EP EP09772849A patent/EP2310010A2/en not_active Withdrawn
-
2010
- 2010-12-20 IL IL210127A patent/IL210127A0/en unknown
- 2010-12-30 EC EC2010010735A patent/ECSP10010735A/es unknown
- 2010-12-30 DO DO2010000408A patent/DOP2010000408A/es unknown
- 2010-12-30 CL CL2010001636A patent/CL2010001636A1/es unknown
- 2010-12-30 HN HN2010002786A patent/HN2010002786A/es unknown
-
2011
- 2011-01-03 SV SV2011003786A patent/SV2011003786A/es unknown
- 2011-01-05 NI NI201100007A patent/NI201100007A/es unknown
- 2011-01-10 CR CR20110016A patent/CR20110016A/es unknown
- 2011-02-01 ZA ZA2011/00844A patent/ZA201100844B/en unknown
- 2011-02-01 CO CO11011427A patent/CO6341555A2/es active IP Right Grant
-
2013
- 2013-02-20 JP JP2013031176A patent/JP2013139459A/ja not_active Ceased
-
2014
- 2014-07-24 US US14/339,981 patent/US20150051185A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP10010735A (es) | Compuestos químicos 251 | |
AU2011338389A8 (en) | Bicyclic compounds as Pim inhibitors | |
GT200800184A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
ECSP088152A (es) | 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización | |
CR9949A (es) | Inhibidores de proteina activadora de la 5-lipoxigenasa (flap) | |
BRPI0721905B8 (pt) | composto inibidor de proteassoma, sua composição farmacêutica e seu uso | |
EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
BRPI0712816B8 (pt) | compostos de pirrolpirimidina e seus usos | |
SV2010003706A (es) | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas | |
UY30578A1 (es) | Nuevos derivados de 2,4??- y 3, 4??-bipiridina sustituidos, procedimientos para su preparacion, medicamentos conteniéndolos y aplicaciones | |
ECSP11011113A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
CR10192A (es) | Compuestos de amido y su uso como productos farmaceuticos | |
PA8719401A1 (es) | Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo | |
BRPI0512352A (pt) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas | |
ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
MX2013012661A (es) | Compuestos de piridazina biciclicos como inhibidores pim. | |
ECSP088252A (es) | 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización | |
GT200800206A (es) | Dimeros de derivados de artemisinina, su preparacion y su aplicacion en terapeutica | |
CU20100032A7 (es) | Depsipéptidos cíclicos | |
UY29358A1 (es) | Tiazolidinonas, su preparacion y su uso como medicamento | |
HN2011000404A (es) | Derivados de enfumafungina y composicion comprendiendo los mismos | |
ATE474574T1 (de) | Imidazoazephinonverbindungen | |
CU20100265A7 (es) | Compuestos químicos 251 | |
EA200702590A1 (ru) | Ингибиторы растворимой аденилатциклазы | |
ECSP088650A (es) | Compuestos de amido y su uso como productos farmaceuticos |